Reviva Pharmaceuticals

66 articles about Reviva Pharmaceuticals

• 

  Clinical Catch-Up: January 10-14

  1/17/2022

  Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.

• Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia

  1/10/2022

  Reviva Pharmaceuticals Holdings, Inc. announced the U.S. Food and Drug Administration has notified the Company that it may proceed with Phase 3 clinical investigation of its lead candidate, brilaroxazine, a novel serotonin and dopamine receptor modulator for the treatment of schizophrenia.

• Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences

  12/20/2021

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings.

• Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights

  8/16/2021

  Reviva Pharmaceuticals Holdings, Inc. today reported financial results for the second quarter of 2021 and summarized recent business highlights.

• Reviva Added to Russell Microcap® Index

  6/28/2021

  Reviva Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, announced it has joined the broad-market Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution.

• Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering

  5/27/2021

  Reviva Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, announced the pricing of its upsized underwritten public offering of 8,000,000 shares of its common stock and accompanying investor warrants to purchase up to 6,000,000 shares of common stock.

• 

  Clinical Catch-Up: April 26-30

  5/3/2021

  Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.

• Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia

  4/26/2021

  Met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder

• Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update

  3/22/2021

  -Closed Merger with Tenzing Acquisition Corp and publicly listed on  NASDAQ Capital Market - -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved-

• Reviva Pharmaceuticals Holdings, Inc. to Present at the Maxim Group Inaugural 2021 Emerging Growth Virtual Conference

  3/11/2021

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that it will present at the Maxim Group Inaugural Emerging Growth Virtual Conference hosted by M-Vest.

• Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc.

  12/14/2020

  Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Reviva Holdings ”), as the successor to Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“ Tenzing ”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“ Reviva ”), a California-based clinical-stage ph

• Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Execution of Definitive Agreement and Plan of Merger for Business Combination

  7/21/2020

  Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (" Tenzing ") (NASDAQ:  TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (" Reviva ") and a California -based clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas

• Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

  6/3/2019

  Reviva Pharmaceuticals, Inc. announced that it has successfully completed a pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration for its drug candidate brilaroxazine, which is being developed for the treatment of idiopathic pulmonary fibrosis.

• Reviva Pharmaceuticals Selected as a Winner of the 2018 Red Herring Top 100 Global Award

  10/29/2018

  Reviva Pharmaceuticals, Inc. announced today that it has been selected as a winner of the 2018 Red Herring Top 100 Global award, which recognizes the leading private companies from North America, Europe, and Asia, celebrating these companies’ innovations and technologies across their respective industries.

• Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

  4/10/2018

  IPF is a devastating disease with limited treatment options and no cure.

• Reviva Pharma Announces Addition Of A New Member To Its Board Of Directors

  7/24/2017

• Reviva Pharma Announces Closing Of Bridge Financing And Addition Of A New Member To Its Board Of Directors

  5/22/2017

• Reviva Pharma Receives FDA Orphan Designation For Pulmonary Arterial Hypertension (PAH)

  11/17/2016

• Reviva Pharma Presented RP5063 Preclinical Efficacy Results For Pulmonary Arterial Hypertension At American Thoracic Society Conference 2016

  5/20/2016

• Reviva Pharmaceuticals Inc Reports RP5063 Positive Efficacy Results For Memory Deficits

  10/22/2015